Biotech News

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

Taysha Gene Therapies (TSHA)Taysha Gene TherapiesPartnership

CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic diseases of the central nervous

Related news

TSHATaysha Gene Therapies2026-10-01 12:00 EST

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

TSHATaysha Gene Therapies2026-11-12 12:30 EST

Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update

OCGNOcugen2026-10-14 10:30 EST

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

OCGNOcugen2026-11-10 12:00 EST

Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN

VTGNVistagen Therapeutics, Inc.2026-10-20 12:30 EST

Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs

SNYSanofi2026-10-01 05:00 EST

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

MXCTMaxCyte2026-11-10 11:00 EST

MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base

SNYSanofi2026-10-01 05:00 EST

Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée

VYGRVoyager Therapeutics2026-10-27 12:01 EST

Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026

MGTXMeiraGTx2026-10-27 12:00 EST

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

Taysha Gene Therapies

CNS Gene Therapy Focus Taysha Gene Therapies develops adeno-associated virus gene therapies for severe monogenic diseases of the central nervous system. Its strategy centers on one-time treatments intended to address the underlying genetic cause of disease. Lead Rett Syndrome Program TSHA-102 is an intrathecally delivered AAV9 gene...

Recent company news

Stock data

Close
3.77 USD
Market cap
1.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States